Time:
Venue: Redeye, Mäster Samuelsgatan 42,
Registration (to attend in person): Please register by email to info@egetis.com
Webcast (no preregistration required): Please follow this link
https://www.redeye.se/events/965111/capital-markets-day-egetis-therapeutics-2
During the event, the Company will provide an update and review of its strategy and pipeline prospects. The presentations will focus on the Company’s drug candidate Emcitate (tiratricol) and the related unmet medical need it will address, development plans, commercial opportunities, and additional activities to create and enhance long-term shareholder value. Presentations will be made by members of Egetis’ management team, as well as invited key opinion leaders. Presentations will be held in English. The webcast will also be available on Egetis webpage www.egetis.com after the event.
Agenda
Time (CET) | Subject | Presenter(s) |
15:00 | Welcome, Corporate strategy and overview | |
15:15 | Development of Emcitate for MCT8 deficiency patients | Westerholm |
15:30 | MCT8 deficiency and the unmet medical need | Dr |
15:50 | Q&A | Bauer & Westerholm |
16:00 | Global plans for commercializing Emcitate | |
16:15 | Understanding MCT8 deficiency patients’ & caregivers’ needs | |
16:30 | Improving disease awareness of MCT8 deficiency | Peter Verwaijen, Global Head of Marketing & Brand Strategy |
16:45 | US launch preparations for Emcitate | |
17:00 | Q&A | Krook, Nicholls, Verwaijen, Bedard, Westerholm |
17:10 | Break | |
17:30 | RTH-beta and the unmet medical need | Dr |
17:50 | Q&A | Moran & Westerholm |
18:00 | Concluding remarks |
© Modular Finance, source